Cell Biology Unit

Visual Universitätsmedizin Mainz

Publications

2022

  • Renaud E, Riegel K, Romero R, Suryamohan K, Distler U, Tenzer S, Schad A, Musholt TJ, Rajalingam K. Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis. Mol Cancer. 2022 Oct 10;21(1):195
  • Romero R, Zarzycka A, Preussner M, Fischer F, Hain T, Herrmann JP, Roth K, Keber CU, Suryamohan K, Raifer H, Luu M, Leister H, Bertrams W, Klein M, Shams-Eldin H, Jacob R, Mollenkopf HJ, Rajalingam K, Visekruna A, Steinhoff U. Selected commensals educate the intestinal vascular and immune system for immunocompetence. Microbiome. 2022 Sep 28;10(1):158. 
  • Chouha, N., H. Abou-Hamdan, H. Yurugi, R. Yoshii, H. Ii, A. Najem, G.E. Ghanem, S. Nakata, K. Rajalingam, Y. Peng, D. Wang, C.G. Nebigil, and L. Desaubry, Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis. Eur J Med Chem, 2022. 242: p. 114635.
  • Eichler, M., U. Distler, U. Nasrullah, A. Krishnan, M. Kaulich, K. Husnjak, W. Eberhardt, K. Rajalingam, S. Tenzer, J. Pfeilschifter, and G. Imre, The caspase-2 substrate p54nrb exhibits a multifaceted role in tumor cell death susceptibility via gene regulatory functions. Cell Death Dis, 2022. 13(4): p. 386.
  • Mooz, J., K. Riegel, H. Ps, A. Sadanandam, F. Marini, M. Klein, U. Werner, W. Roth, A. Wilken-Schmitz, I. Tegeder, and K. Rajalingam, ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers. Sci Adv, 2022. 8(11): p. eabk1538.
  • Fester, N., E. Zielonka, J. Goldmann, A.S. Frombach, U. Muller-Kuller, N. Gutfreund, K. Riegel, J.G.A. Smits, E. Schleiff, K. Rajalingam, H. Zhou, S. Simm, and V. Dotsch, Enhanced pro-apoptosis gene signature following the activation of TAp63alpha in oocytes upon gamma irradiation. Cell Death Dis 13, 204 (2022).
  • Stickdorn, J., L. Stein, D. Arnold-Schild, J. Hahlbrock, C. Medina-Montano, J. Bartneck, T. Ziss, E. Montermann, C. Kappel, D. Hobernik, M. Haist, H. Yurugi, M. Raabe, A. Best, K. Rajalingam, M.P. Radsak, S.A. David, K. Koynov, M. Bros, S. Grabbe, H. Schild, and L. Nuhn, Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano. 2022 Mar 22;16(3):4426-4443
  • Mu H, Zeng Y, Zhuang Y, Gao W, Zhou Y, Rajalingam K, Zhao W: Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays. Nano Lett. 2022, 22, 3, 1007–1016.

2021

  • Riegel, K., Yurugi, H., Schlöder, J., Jonuleit H, Kaulich M, Kirschner F, Arnold-Schild D, Tenzer S, Schild H, Rajalingam K. ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. Cell Death Dis 12, 969 (2021).

  • Goranci-Buzhala G, Mariappan A, Ricci-Vitiani L, Josipovic N, Pacioni S, Gottardo M, Ptok J, Schaal H, Callaini G, Rajalingam K, Dynlacht B, Hadian K, Papantonis A, Pallini R, Gopalakrishnan J. Cilium induction triggers differentiation of glioma stem cells. Cell Rep. 2021;36(10):109656.
  • Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, Hei-Yin Cheung H, Wong KB, Ng WL, Cinatl J, Geurink PP, van der Heden van Noort GJ, Rajalingam K, Ciesek S, Hummer G, Dikic I. Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. J Biol Chem. 2021 Aug;297(2):100925.
  • Imre G, Krahling V, Eichler M, Trautmann S, Ferreiros N, Aman MJ, Kashanchi F, Rajalingam K, Pohlmann S, Becker S, Heringdorf DMZ, Pfeilschifter J. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. iScience. 2021 Mar 5;24(4):102266.

2020

  • Sadanandam A, Bopp T, Dixit S, Knapp DJHF, Emperumal CP, Vergidis P, Rajalingam K, Melcher A, Kannan N. A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell Death Discov. 2020 Dec 8;6(1):141.

  • Bogucka, K., Marini, F., Rosigkeit, S., Schloeder J., Jonuleit H., David K., Schlackow M., Rajalingam K. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. Cancer Gene Ther. 2021 May;28(5):359-374.
  • Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, Schulz L, Widera M, Mehdipour AR, Tascher G, Geurink PP, Wilhelm A, van der Heden van Noort GJ, Ovaa H, Muller S, Knobeloch KP, Rajalingam K, Schulman BA, Cinatl J, Hummer G, Ciesek S, Dikic I. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.  Nature. 2020 Nov;587(7835):657-662.
  • Yurugi H, Zhuang Y, Siddiqui FA, Liang H, Rosigkeit S, Zeng Y, Abou-Hamdan H, Bockamp E, Zhou Y, Abankwa D, Zhao W, Desaubry L, Rajalingam K. A subset of flavaglines inhibits KRAS nanoclustering and activation. J Cell Sci. 2020 Jun 24;133(12):jcs244111.
  • Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A, Rajalingam K, Chantry AD, Irvine AE. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. 2020 Jul;39(27):5001-5014. 
  • Krishnan A, Berthelet J, Renaud E, Rosigkeit S, Distler U, Stawiski E, Wang J, Modrusan Z, Fiedler M, Bienz M, Tenzer S, Schad A, Roth W, Thiede B, Seshagiri S, Musholt TJ, Rajalingam K. Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas. Nat Commun. 2020 Apr 28;11(1):2056.
  • Bogucka K, Pompaiah M, Marini F, Binder H, Harms G, Kaulich M, Klein M, Michel C, Radsak MP, Rosigkeit S, Grimminger P, Schild H, Rajalingam K. ERK3/MAPK6 controls IL-8 production and chemotaxis. Elife. 2020 Apr 21;9:e52511. 
  • Wiechmann S, Maisonneuve P, Grebbin BM, Hoffmeister M, Kaulich M, Clevers H, Rajalingam K, Kurinov I, Farin HF, Sicheri F, Ernst A. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids. J Biol Chem. 2020;295(14):4526-40.
  • Wang D, Tabti R, Elderwish S, Abou-Hamdan H, Djehal A, Yu P, Yurugi H, Rajalingam K, Nebigil CG, Desaubry L. Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases. Cell Mol Life Sci. 2020 Sep;77(18):3525-3546.

2019

  • Werner A, Pieh D, Echchannaoui H, Rupp J, Rajalingam K, Theobald M, Closs EI, Munder M. Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. Front Oncol. 2019 Nov 20;9:1268.
  • Staubitz JI, Musholt TJ, Schad A, Springer E, Lang H, Rajalingam K, Roth W, Hartmann N. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma. Cancer Genet. 2019 Oct;238:10-17.
  • Visekruna A, Hartmann S, Sillke YR, Glauben R, Fischer F, Raifer H, Mollenkopf H, Bertrams W, Schmeck B, Klein M, Pagenstecher A, Lohoff M, Jacob R, Pabst O, Bland PW, Luu M, Romero R, Siegmund B, Rajalingam K, Steinhoff U. Intestinal development and homeostasis require activation and apoptosis of diet-reactive T cells.  J Clin Invest. 2019 Apr 2;129(5):1972-1983.

2018

  • Staubitz JI, Schad A, Springer E, Rajalingam K, Lang H, Roth W, Hartmann N, Musholt TJ. Novel rearrangements involving the RET gene in papillary thyroidcarcinoma. Cancer Genet. 2019 Jan;230:13-20. 
  • Kumaraswamy A, Mamidi A, Desai P, Sivagnanam A, Perumalsamy LR, Ramakrishnan C, Gromiha M, Rajalingam K, Mahalingam S. The non-enzymatic RAS effector RASSF7inhibits oncogenic c-Myc function.  J Biol Chem. 2018 Oct 5;293(40):15691-15705.
  • Buehler U, Schulenburg K, Yurugi H, Šolman M, Abankwa D, Ulges A, Tenzer S, Bopp T, Thiede B, Zipp F, Rajalingam K. Targeting prohibitins at the cell surfaceprevents Th17-mediated autoimmunity. EMBO J. 2018 Aug 15;37(16):e99429. 
  • Wüstenhagen E, Boukhallouk F, Negwer I, Rajalingam K, Stubenrauch F, Florin L.The Myb-related protein MYPOP is a novel intrinsic host restriction factor ofoncogenic human papillomaviruses. Oncogene. 2018 Nov;37(48):6275-6284. 
  • Karthik IP, Desai P, Sukumar S, Dimitrijevic A, Rajalingam K, Mahalingam S.E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 functionthrough histone methyltransferases. J Biol Chem. 2018 Apr 13;293(15):5624-5635.

2017

  • Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, Desaubry L, Rajalingam K. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Oncogene. 2017 Aug 17;36(33):4778-4789.
  • Lacher SM, Bruttger J, Kalt B, Berthelet J, Rajalingam K, Wortge S, Waisman A. HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival. Cell Death Dis. 2017 May 25;8(5):e2824.
  • Imre G, Berthelet J, Heering J, Kehrloesser S, Melzer IM, Lee BI, Thiede B, Dotsch V, Rajalingam K. Apoptosis inhibitor 5 is an endogenous inhibitor of caspase-2. EMBO Rep. 2017 May;18(5):733-744. 

2016 - 2014

2016

  • Liu X, Huai J, Endle H, Schlüter L, Fan W, Li Y, Richers S, Yurugi H, Rajalingam K, Ji H, Cheng H, Rister B, Horta G, Baumgart J, Berger H, Laube G,Schmitt U, Schmeisser MJ, Boeckers TM, Tenzer S, Vlachos A, Deller T, Nitsch R,Vogt J. PRG-1 Regulates Synaptic Plasticity via Intracellular PP2A/β1-IntegrinSignaling. Dev Cell. 2016 Aug 8;38(3):275-90. doi: 10.1016/j.devcel.2016.06.019. Epub 2016 Jul 21. PubMed PMID: 27453502.

  • Rajalingam K, Dikic I. SnapShot: Expanding the Ubiquitin Code. Cell. 2016 Feb25;164(5):1074-1074.e1. doi: 10.1016/j.cell.2016.02.019. PubMed PMID: 26919436.

2015

  • Maus F, Sakry D, Binamé F, Karram K, Rajalingam K, Watts C, Heywood R, Krüger R, Stegmüller J, Werner HB, Nave KA, Krämer-Albers EM, Trotter J. The NG2Proteoglycan Protects Oligodendrocyte Precursor Cells against Oxidative Stressvia Interaction with OMI/HtrA2. PLoS One. 2015 Sep 4;10(9):e0137311. doi:10.1371/journal.pone.0137311. eCollection 2015. PubMed PMID: 26340347; PubMedCentral PMCID: PMC4560422.
  • Dubrez L, Rajalingam K. IAPs and cell migration. Semin Cell Dev Biol. 2015Mar;39:124-31. doi: 10.1016/j.semcdb.2015.02.015. Epub 2015 Mar 10. Review.PubMed PMID: 25769935.
  • Ulges A, Klein M, Reuter S, Gerlitzki B, Hoffmann M, Grebe N, Staudt V,Stergiou N, Bohn T, Brühl TJ, Muth S, Yurugi H, Rajalingam K, Bellinghausen I,Tuettenberg A, Hahn S, Reißig S, Haben I, Zipp F, Waisman A, Probst HC, Beilhack A, Buchou T, Filhol-Cochet O, Boldyreff B, Breloer M, Jonuleit H, Schild H,Schmitt E, Bopp T. Protein kinase CK2 enables regulatory T cells to suppressexcessive TH2 responses in vivo. Nat Immunol. 2015 Mar;16(3):267-75. doi:10.1038/ni.3083. Epub 2015 Jan 19. PubMed PMID: 25599562.

2014

  • McEwan DG, Richter B, Claudi B, Wigge C, Wild P, Farhan H, McGourty K, Coxon FP, Franz-Wachtel M, Perdu B, Akutsu M, Habermann A, Kirchof A, Helfrich MH,Odgren PR, Van Hul W, Frangakis AS, Rajalingam K, Macek B, Holden DW, Bumann D,Dikic I. PLEKHM1 regulates Salmonella-containing vacuole biogenesis andinfection. Cell Host Microbe. 2015 Jan 14;17(1):58-71. doi:10.1016/j.chom.2014.11.011. Epub 2014 Dec 11. PubMed PMID: 25500191.
  • Schulenburg K, Glatz G, Remenyi A, Rajalingam K. Divide and rule: The role of ubiquitination in inactivation of the ERK5-MAPK cascade. Mol Cell Oncol. 2014 Nov11;1(4):e969170. doi: 10.4161/23723548.2014.969170. eCollection 2014 Oct-Dec.PubMed PMID: 27308375; PubMed Central PMCID: PMC4905217.
  • Mooz J, Oberoi-Khanuja TK, Harms GS, Wang W, Jaiswal BS, Seshagiri S,Tikkanen R, Rajalingam K. Dimerization of the kinase ARAF promotes MAPK pathwayactivation and cell migration. Sci Signal. 2014 Aug 5;7(337):ra73. doi:10.1126/scisignal.2005484. PubMed PMID: 25097033.
  • Takeda AN, Oberoi-Khanuja TK, Glatz G, Schulenburg K, Scholz RP, Carpy A, Macek B, Remenyi A, Rajalingam K. Ubiquitin-dependent regulation of MEKK2/3-MEK5-ERK5 signaling module by XIAP and cIAP1. EMBO J. 2014 Aug18;33(16):1784-801. doi: 10.15252/embj.201487808. Epub 2014 Jun 28. PubMed PMID: 24975362; PubMed Central PMCID: PMC4195761.
  • Oberoi-Khanuja TK, Rajalingam K. Ubiquitination of Rac1 by inhibitors ofapoptosis (IAPs). Methods Mol Biol. 2014;1120:43-54. doi:10.1007/978-1-62703-791-4_4. PubMed PMID: 24470018.

2013 - 2008

2013

  • Hornburger MC, Mayer BA, Leonhardt S, Willer EA, Zahler S, Beyerle A, Rajalingam K, Vollmar AM, Fürst R. A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoAactivation. FASEB J. 2014 Apr;28(4):1938-46. doi: 10.1096/fj.13-235754. Epub 2013Dec 26. PubMed PMID: 24371121.
  • Murali A, Rajalingam K. Small Rho GTPases in the control of cell shape andmobility. Cell Mol Life Sci. 2014 May;71(9):1703-21. doi:10.1007/s00018-013-1519-6. Epub 2013 Nov 26. Review. PubMed PMID: 24276852.
  • Camargo LL, Babelova A, Mieth A, Weigert A, Mooz J, Rajalingam K, Heide H,Wittig I, Lopes LR, Brandes RP. Endo-PDI is required for TNFα-inducedangiogenesis. Free Radic Biol Med. 2013 Dec;65:1398-1407. doi:10.1016/j.freeradbiomed.2013.09.028. Epub 2013 Oct 5. PubMed PMID: 24103565.
  • Yurugi H, Rajalingam K. A role for prohibitin in mast cell activation:location matters. Sci Signal. 2013 Sep 10;6(292):pe29. doi:10.1126/scisignal.2004646. PubMed PMID: 24023253.
  • Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX,de Sauvage FJ, Seshagiri S. Oncogenic ERBB3 mutations in human cancers. CancerCell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Erratum in:Cancer Cell. 2014 Apr 14;25(4):543-4. PubMed PMID: 23680147.

2012

  • Rajalingam K, Rudel T. "Prohibitin"g CRAF/MAPK activation with rocaglamides. Chem Biol. 2012 Sep 21;19(9):1077-8. doi: 10.1016/j.chembiol.2012.09.004. PubMed PMID: 22999872.
  • Imre G, Rajalingam K. Role for caspase-2 during pore-forming toxin-mediatedapoptosis. Cell Cycle. 2012 Oct 15;11(20):3709-10. doi: 10.4161/cc.22046. Epub2012 Sep 14. PubMed PMID: 22983006; PubMed Central PMCID: PMC3495804.
  • Oberoi-Khanuja TK, Rajalingam K. IAPs as E3 ligases of Rac1: shaping themove. Small GTPases. 2012 Apr-Jun;3(2):131-6. doi: 10.4161/sgtp.19988. PubMedPMID: 22790203; PubMed Central PMCID: PMC3408978.
  • Fulda S, Rajalingam K, Dikic I. Ubiquitylation in immune disorders andcancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med. 2012Jul;4(7):545-56. doi: 10.1002/emmm.201100707. Epub 2012 Jun 25. Review. PubMedPMID: 22730341; PubMed Central PMCID: PMC3407942.
  • Oberoi-Khanuja TK, Karreman C, Larisch S, Rapp UR, Rajalingam K. Role ofmelanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAPrepeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration. J Biol Chem. 2012 Aug 17;287(34):28445-55. doi: 10.1074/jbc.M112.341297. Epub2012 Jun 18. PubMed PMID: 22711539; PubMed Central PMCID: PMC3436542.
  • Imre G, Heering J, Takeda AN, Husmann M, Thiede B, zu Heringdorf DM, GreenDR, van der Goot FG, Sinha B, Dötsch V, Rajalingam K. Caspase-2 is an initiatorcaspase responsible for pore-forming toxin-mediated apoptosis. EMBO J. 2012 May30;31(11):2615-28. doi: 10.1038/emboj.2012.93. Epub 2012 Apr 24. PubMed PMID:22531785; PubMed Central PMCID: PMC3365430.
  • Bull VH, Rajalingam K, Thiede B. Sorafenib-induced mitochondrial complex Iinactivation and cell death in human neuroblastoma cells. J Proteome Res. 2012 Mar 2;11(3):1609-20. doi: 10.1021/pr200790e. Epub 2012 Feb 15. PubMed PMID:22268697.
  • Amaddii M, Meister M, Banning A, Tomasovic A, Mooz J, Rajalingam K, Tikkanen R. Flotillin-1/reggie-2 protein plays dual role in activation ofreceptor-tyrosine kinase/mitogen-activated protein kinase signaling. J Biol Chem.2012 Mar 2;287(10):7265-78. doi: 10.1074/jbc.M111.287599. Epub 2012 Jan 9. PubMedPMID: 22232557; PubMed Central PMCID: PMC3293549.

2011

  • Bornstein B, Edison N, Gottfried Y, Lev T, Shekhtman A, Gonen H, Rajalingam K, Larisch S. X-linked Inhibitor of Apoptosis Protein promotes the degradation ofits antagonist, the pro-apoptotic ARTS protein. Int J Biochem Cell Biol. 2012Mar;44(3):489-95. doi: 10.1016/j.biocel.2011.12.005. Epub 2011 Dec 14. PubMedPMID: 22185822.
  • Oberoi TK, Dogan T, Hocking JC, Scholz RP, Mooz J, Anderson CL, Karreman C,Meyer zu Heringdorf D, Schmidt G, Ruonala M, Namikawa K, Harms GS, Carpy A, MacekB, Köster RW, Rajalingam K. IAPs regulate the plasticity of cell migration bydirectly targeting Rac1 for degradation. EMBO J. 2012 Jan 4;31(1):14-28. doi:10.1038/emboj.2011.423. Epub 2011 Nov 25. PubMed PMID: 22117219; PubMed CentralPMCID: PMC3252583.
  • Imre G, Larisch S, Rajalingam K. Ripoptosome: a novel IAP-regulated celldeath-signalling platform. J Mol Cell Biol. 2011 Dec;3(6):324-6. doi:10.1093/jmcb/mjr034. Epub 2011 Nov 23. PubMed PMID: 22114055.

  • Rajalingam K, Dikic I. Healthy ageing through regulated proteostasis. EMBO J.2011 Aug 3;30(15):2983-5. doi: 10.1038/emboj.2011.237. PubMed PMID: 21811299;PubMed Central PMCID: PMC3160197.
  • Rajalingam K, van der Goot FG. When cells and microbes meet in Krakow. EMBO Rep. 2011 Mar;12(3):188-90. doi: 10.1038/embor.2011.27. Epub 2011 Feb 25. PubMed PMID: 21350503; PubMed Central PMCID: PMC3059901.
  • Lückerath K, Kirkin V, Melzer IM, Thalheimer FB, Siele D, Milani W, Adler T, Aguilar-Pimentel A, Horsch M, Michel G, Beckers J, Busch DH, Ollert M,Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Staal FJ, Rajalingam K, Hueber AO, Strobl LJ, Zimber-Strobl U, Zörnig M. Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas liganddomain. Blood. 2011 Jan 13;117(2):519-29. doi: 10.1182/blood-2010-07-292722. Epub2010 Oct 22. PubMed PMID: 20971954.

2009

  • Kozjak-Pavlovic V, Dian-Lothrop EA, Meinecke M, Kepp O, Ross K, Rajalingam K, Harsman A, Hauf E, Brinkmann V, Günther D, Herrmann I, Hurwitz R, Rassow J,Wagner R, Rudel T. Bacterial porin disrupts mitochondrial membrane potential and sensitizes host cells to apoptosis. PLoS Pathog. 2009 Oct;5(10):e1000629. doi:10.1371/journal.ppat.1000629. Epub 2009 Oct 23. PubMed PMID: 19851451; PubMedCentral PMCID: PMC2759283.
  • Morand PC, Drab M, Rajalingam K, Nassif X, Meyer TF. Neisseria meningitidisdifferentially controls host cell motility through PilC1 and PilC2 components of type IV Pili. PLoS One. 2009 Aug 31;4(8):e6834. doi:10.1371/journal.pone.0006834. PubMed PMID: 19718432; PubMed Central PMCID:PMC2729722.
  • Kepp O, Gottschalk K, Churin Y, Rajalingam K, Brinkmann V, Machuy N, Kroemer G, Rudel T. Bim and Bmf synergize to induce apoptosis in Neisseria gonorrhoeaeinfection. PLoS Pathog. 2009 Mar;5(3):e1000348. doi:10.1371/journal.ppat.1000348. Epub 2009 Mar 20. PubMed PMID: 19300516; PubMedCentral PMCID: PMC2654407.

  • Rajalingam K, Dikic I. Inhibitors of apoptosis catch ubiquitin. Biochem J. 2009 Jan 1;417(1):e1-3. doi: 10.1042/BJ20082215. PubMed PMID: 19061481.
  • Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R, AlbertS, Rajalingam K, Hekman M, Rapp UR. Regulation of RAF activity by 14-3-3proteins: RAF kinases associate functionally with both homo- and heterodimericforms of 14-3-3 proteins. J Biol Chem. 2009 Jan 30;284(5):3183-94. doi:10.1074/jbc.M804795200. Epub 2008 Dec 2. PubMed PMID: 19049963.

2008

  • Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, Rapp UR, Rajalingam K. X-linked and cellular IAPs modulate the stability of C-RAF kinaseand cell motility. Nat Cell Biol. 2008 Dec;10(12):1447-55. doi: 10.1038/ncb1804. Epub 2008 Nov 16. Erratum in: Nat Cell Biol. 2009 Jan;11(1):110. PubMed PMID:19011619.

  • Rajalingam K, Sharma M, Lohmann C, Oswald M, Thieck O, Froelich CJ, Rudel T. Mcl-1 is a key regulator of apoptosis resistance in Chlamydiatrachomatis-infected cells. PLoS One. 2008 Sep 1;3(9):e3102. doi:10.1371/journal.pone.0003102. PubMed PMID: 18769617; PubMed Central PMCID:PMC2518856.
  • Samoylenko A, Byts N, Rajalingam K, von Ahsen N, Rapp UR, Ehrenreich H, SirénAL. Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling. Cell Signal. 2008 Jan;20(1):154-62. Epub 2007 Oct 12. PubMed PMID: 18006272.

2007 - 2004

  • Rajalingam K, Oswald M, Gottschalk K, Rudel T. Smac/DIABLO is required foreffector caspase activation during apoptosis in human cells. Apoptosis. 2007Aug;12(8):1503-10. PubMed PMID: 17440818.

  • Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and theirdownstream targets. Biochim Biophys Acta. 2007 Aug;1773(8):1177-95. Epub 2007 Jan28. Review. PubMed PMID: 17428555.
  • Kepp O, Rajalingam K, Kimmig S, Rudel T. Bak and Bax are non-redundant duringinfection- and DNA damage-induced apoptosis. EMBO J. 2007 Feb 7;26(3):825-34.Epub 2007 Jan 18. PubMed PMID: 17235284; PubMed Central PMCID: PMC1794390.

  • Rajalingam K, Sharma M, Paland N, Hurwitz R, Thieck O, Oswald M, Machuy N,Rudel T. IAP-IAP complexes required for apoptosis resistance of C.trachomatis-infected cells. PLoS Pathog. 2006 Oct;2(10):e114. PubMed PMID:17069460; PubMed Central PMCID: PMC1626104.
  • Paland N, Rajalingam K, Machuy N, Szczepek A, Wehrl W, Rudel T. NF-kappaB andinhibitor of apoptosis proteins are required for apoptosis resistance ofepithelial cells persistently infected with Chlamydophila pneumoniae. Cell Microbiol. 2006 Oct;8(10):1643-55. PubMed PMID: 16984419.

  • Rajalingam K, Rudel T. Ras-Raf signaling needs prohibitin. Cell Cycle. 2005Nov;4(11):1503-5. Epub 2005 Nov 1. Review. PubMed PMID: 16294014.

  • Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, Rapp UR, Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation andepithelial cell migration. Nat Cell Biol. 2005 Aug;7(8):837-43. Epub 2005 Jul 24.PubMed PMID: 16041367.
  • Machuy N, Thiede B, Rajalingam K, Dimmler C, Thieck O, Meyer TF, Rudel T. Aglobal approach combining proteome analysis and phenotypic screening with RNAinterference yields novel apoptosis regulators. Mol Cell Proteomics. 2005Jan;4(1):44-55. Epub 2004 Nov 26. PubMed PMID: 15567892.
ncb-v7-n8.gif
Sci_Signaling_cover.gif
elife_cove.pdf